Skip to main content
. Author manuscript; available in PMC: 2015 Jun 15.
Published in final edited form as: Clin Cancer Res. 2014 Jun 15;20(12):3222–3232. doi: 10.1158/1078-0432.CCR-13-3227

Figure 6.

Figure 6

Systemic ICI treatment inhibits macrophage activation. A. LCC9 tumor sections from tumor treated with Control, HCQ, ICI, ICI+HCQ, TAM, or TAM+HCQ were stained for CD68 a marker of macrophages. B. Peripheral macrophages were quantified as cells per section. n=4-8; *p<0.05 C. ERα and GPR30 expression was determined in LCC9, MCF7-RR, U937 (undifferentiated monocytes), and U937 (differentiated macrophages) protein lysates by Western blot hybridization. D. U937 cells differentiated into macrophages in the presence of vehicle control, HCQ, ICI, ICI+HCQ, TAM, or TAM+HCQ were added to pre-plated MDA-MB-231 ER- breast cancer cells (1:5 ratio macrophages: cancer cells) and cell index was measured by electrical impedance over 72 hours. n=3; *p<0.05